Scott B. Willoughby - Aug 2, 2021 Form 3 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
SVP, Gen. Counsel & Secretary
Signature
/s/ Matthew Colvin, Attorney-in-Fact for Scott B. Willoughby
Stock symbol
SGMO
Transactions as of
Aug 2, 2021
Transactions value $
$0
Form type
3
Date filed
8/9/2021, 08:21 PM
Next filing
Aug 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SGMO Common Stock 47.1K Aug 2, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGMO Stock Option (Right to Buy) Aug 2, 2021 Common Stock 69K $8.32 Direct F3
holding SGMO Stock Option (Right to Buy) Aug 2, 2021 Common Stock 27.5K $11.19 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes: (a) 23,201 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on April 24, 2020; and (b) 13,750 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021. All such RSUs vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")) through such dates and subject to acceleration as provided in the 2018 EIP, as amended.
F2 Includes 810 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 10, 2020. The RSUs will vest in two equal remaining installments on October 29, 2021 and April 29, 2022, subject to the Reporting Person's Continuous Service through such dates and subject to acceleration as provided in the 2018 EIP, as amended.
F3 One-quarter (1/4) of the stock option vested and became exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the April 24, 2020 grant date, thereafter the stock option began to vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.
F4 One-quarter (1/4) of the stock option will vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder of the stock option will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended.